TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates
Portfolio Pulse from
TScan Therapeutics, Inc. (TCRX) reported a Q4 loss of $0.29 per share, missing the Zacks Consensus Estimate of a $0.27 loss. This is a larger loss compared to $0.21 per share a year ago.
March 05, 2025 | 2:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
TScan Therapeutics reported a larger-than-expected Q4 loss of $0.29 per share, missing the Zacks Consensus Estimate of $0.27. This marks an increase from the $0.21 loss per share a year ago.
The reported loss per share of $0.29 is worse than the expected $0.27, indicating a negative earnings surprise. This, combined with a year-over-year increase in losses, is likely to negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100